Report Overview
The Global Molecular Biology Enzymes Market size is expected to be worth around USD 58.6 Billion by 2033 from USD 23.01 Billion in 2023, growing at a CAGR of 9.8% during the forecast period from 2024 to 2033.
A branch of biology that focuses on studying biological processes at the molecular level, particularly the interactions between various molecules essential for life is known as molecular biology. The field explores the structure, function, and regulation of molecules such as DNA, RNA, proteins, and small molecules, within cells and organisms. The most essential tools used in this field includes molecular biology enzymes, kits and reagents.
Molecular biology enzymes are specialized proteins significant for managing and controlling DNA, RNA and protein activities within the cell, and are designed to facilitate various molecular biology techniques, such as RNA and DNA manipulation, polymerase chain reaction, cloning, sequencing, gene expression analysis and protein purification.
One notable enzyme in DNA polymerase, responsible for crafting new strands during replication, ensuring the accurate transfer of genetic information. Restriction enzymes play pivotal role in molecular biology, cutting down DNA at specific recognition sites and enabling the manipulation of genetic material. Thus, these enzymes used in molecular biology enables researchers to study and manipulate nucleic acids and proteins precisely, advancing our understanding of cellular processes and facilitating various biotechnological and biomedical applications.
In recent years, there has been a surging case of genetic disorders diagnosed all around the world, which is robustly driving the global molecular biology enzymes, kits, and reagents market growth. A huge revolution was brought up through COVID 19 pandemic, resulting the pharmaceutical and biotechnology companies to focus on work addressing COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges.
Key Takeaways
- Based on product, kits and reagents segment rules the entire molecular biology enzymes market in the year 2023.
- Based on application, an impressive market revenue share of 39.5% is accounted by sequencing segment.
- Based on end use, pharmaceutical and biotechnology companies held a prominent market revenue share of 40.1%.
- North America mark its dominance in the global molecular biology enzymes market occupying a praise worthy market revenue share of 36.4% in the year 2023
Product Analysis
Kits and Reagents segment marks dominance in the market
Based on product, the market is broadly classified into enzymes, Kits and Reagent segments. Amongst these, kits and reagents segment withheld a remarkable market revenue share of 78.6%, showcasing domination over global molecular biology enzymes market in the year 2023. The dominance can be attributed to the vast availability of these products in the market space, novel developments and continuous product launches from key players, which are further fostered by the escalating cases of SARS-CoV-2 variants.
- PerkinElmer announced the launch of NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 in December 2021 for disease surveillance and enhancement of sequencing throughput and reliability for variant identification.
The enzyme segment on the other hand, is anticipated to showcase fastest growth, with continuous growth of cloning technology as a routine laboratory practice coupled with rising scope in molecular biology. This enables the manufacturers and suppliers to provide multiple enzymes for nucleic acid manipulation. Cloning techniques excelled with the presence of diverse enzymes including polymerases, ligases, nucleases, methylases, and topoisomerases for cloning applications. Many major companies are emphasizing to develop novel and advanced enzymes.
- In November 2021, Novozymes and Novo Nordisk established a collab to develop specialty enzymes for applications in biopharmaceutical production processes and are projected to lauch new product in the upcoming years.
Application Analysis
Sequencing segment underscored its importance
Based on applications, the molecular biology enzymes market is fragmented into Polymerase Chain Reaction, Sequencing, Cloning, Epigenetics, Restriction Digestion and other segments. A major portion within the market is occupied by sequencing segment. Increasing implementation of sequencing based medical treatments and applications of sequencing in oncology enables the segment to grab a valuable revenue share of 39.5% in the year 2023.
Furthermore, the usage of next generation sequencing for analysis of genomics, tumor diagnostics and biomarker discovery boosts segmental growth and thrives the use of molecular biology consumables under this segment. In addition, major industry players are entering the competition with diverse growth strategies, resulting into market growth.
- In January 2022, a collaboration was established between Pacific Biosciences and Berry Genomics for extending the use of its long read sequencing technology to the clinical market in China.
Polymerase Chain Reaction segment showcases a steady growth in recent years. The segment witnessed a boosted demand with rise in COVID 19 cases resulting into increased production of real-time PCR based detection kits as PCR tests became the golden standard for detection of COVID 19.
- According to National Institute of health, out of 110.5 million tests performed during pandemic, 54.79 million tests were performed using molecular method.
End-User Analysis
Pharma & Biotech Companies makes more use of molecular biology enzymes
Based on end use, the global molecular biology enzymes market is bifurcated into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies and Hospitals & Diagnostic laboratories segment. Owing to wide acceptance of molecular biology products such as PCR, sequencing, genotyping, and DNA/RNA extraction enzymes, pharma and biotech companies segment came up as the frontrunner, capturing a commendable revenue share of 40.1% in the year 2023. The aforementioned products proves to be efficient during research for drug candidates, personalized medicines, or diagnostics of the pharma and biotech companies, fueling advancements of offerings and consequently increases their sales.
Another significant market portion is withheld by academic and research institute segment in 2023. The demand for kits and reagents in research institutes surged with the increasing ultimatum for new diagnostic tools and treatment options for COVID 19 infection. Another crucial factor pushing growth of the segment includes government funding schemes towards these institutes.
- In April 2021, National Institute of Health awarded a grant worth the USD 8 million to the University of Arkansas for the establishment of the Arkansas Integrative Metabolic Research Centre, which would function as a Center for Biomedical Research Excellence.
Key Segments
By Product
- Kits & Reagents
- Enzymes
By Application
- Polymerase Chain Reaction
- Sequencing
- Cloning
- Epigenetics
- Restriction Digestion
- Other
By End user
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospitals & Diagnostic laboratories
Market Drivers
Escalating funding supports the market growth
Few years back genomic equencing was restricted to research facilitites. Fortunately, it has now become one of the common technique in clinical plactices. In the upcoming years healthcare sector is anticipated to generate genomic data of over 60 million patient. The growing implementation of genomic sequencing into healthcare systems is significantly supported by substantial government investments, totaling over the USD 4 billion in at least 14 countries.
World’s largest genome project as part of 200 million public private collaboration among charitable organization and pharmaceutical companies has been announced by united Kingdom. The country has already developed the world’s largest genome database through the 100,000 genome projects. The project was initiated to support researchers and industries through funds to combine data and real world evidence obtained from UK health services. Such enormous fundings by manufacturers and government in the field of genomics is supporting the molecular biology enzymes market growth.
- In November 2018, Stilla Technologies (France), announced the completion of a Series A funding round, gathering the USD 18.3 million in funds, the round was led by Illumina Ventures.
- In August 2018, Nebula Gnomics, along with 10 leading venture capital firms, raised the USD 4.3 million in seed funding, as a part of partnership with Veritas Genetics, a genome sequencing company.
- In April 2020, a genetic diagnostic, research and data company, MedGenome, raised the USD 55 million in a new round of funding, led by LeapFrog Investments, a global impact investment firm.
Market Restraints
The global molecular biology enzymes market may impede its growth by virtue of limited access to technology, hindering the adoption and utilization of products in certain regions and institutions. Many laboratories struggle to acquire necessary equipment and expertise to effectively utilize molecular biology tools, especially in areas lacking infrastructure and resources for advanced molecular biology research, such as developing countries and rural areas.
Many small research institutions or acedmic labs comprising limited funding may face challenges investing in expensive technologies necessary for molecular biology experiments. Lack of technology limits the demand for molecular biology enzymes, which further limits molecular biology enzymes market growth opportunities.
Opportunities
Rising product launches and investments pushes the market growth
The market for molecular biology enzymes witnesses tremendous growth opportunities with the rise in the launch of new molecular biology enzymes used in diverse molecular biology techniques like PCR, NGS, cloning, etc.
- In March 2021, Promega Corporation launched XpressAmpTM Direct Amplification Reagents, which allow sample preparation without RNA extraction and are compatible with automation.
- In November 2022, a new series of qPCR reagent mixes:ClaraTM Probe mix, ClaraTM Probe 1-Step Mix, and ClaraTM HRM mix was introduced by PCR Biosystems.
Another factor providing growth opportunities includes notable technological advancements and research and development investments. China is one of the biggest R&D investor, and is further anticipated to surpass the United States in this regard. Spending of research and development increased the nation from 10.3% in 2020 to the USD 378 billion.
Latest Trends
Bioinformatics and Computational Enzymes Design: The insilico production and engineering of enzymes with desired properties has become possible by virtue of advances in computational biology and enzyme design algorithms. Computational tools for protein modelling, virtual screening and enzyme optimization has become integral tp enzyme development process.
Enzymes for Protein Engineering and Synthetic Biology: There is a need for enzymes facilitating protein engineering, directed evolution and metabolic pathway engineering with the expansion of synthetic biology applications. Customized biological systems and production of bio-based products has become possible with molecular biology enzymes comprising novel and engineering properties.
Impact of Macroeconomic Factors
Inflation is one of the most influential macoeconomic factors, which has had a significant impact on the Molecular biology enzymes Market. The prices of products and services have reached an all time high, which has caused tremendous damages to the economy. The input costs have increased, which accompanied by increased severity of labor shortages, fuel the inflation further. With factors such as these, production costs rise, ultimately leading businesses to be more restrained in their expenditure on research and development.
Regional Analysis
North America Holds Region Accounted for a Significant Share of the Global Molecular Biology Enzymes Market
North America mark its dominance in the global molecular biology enzymes market occupying a praise worthy market revenue share of 36.4% in the year 2023. This owes to the regions’ strong infrastructure for cutting edge biotechnology and healthcare research and development. Prominent industry players operating in molecular biology enzyme field exists in the region, resulting in promotion of enzyme uptake and innovation.
In addition to this, an ultimatum for molecular biology enzymes also scaled with high frequency of chronic diseases and a significant focus on personalized therapy in the region. Furthermore, North America solidifies its position in the market with robust regulatory infrastructure and significant investments in life sciences research, thus leading to market expansion.
Key Regions and Countries Covered in this Report
North America
- The US
- Canada
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherland
- Rest of Europe
APAC
- China
- Japan
- South Korea
- India
- Australia
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
Key Players Analysis
A multitude of key players operate the global molecular biology enzymes market which leads to the market being in a constant state of flux. Several strategies are implemented by the leading players in the market, which assist the businesses in increasing their market shares. Examples include partnerships, strategic investments, mergers and acquisitions. Seeing that the market is fragmented, the overall extent of competition is high.
Market Key Players
Listed below are some of the major players in the industry
- Illumina Inc.
- Thermo Fisher Scientific, Inc.
- Agilent Technologies
- Merck KGaA
- Takara Bio Inc.
- Promega Corporation
- New England Biolabs Inc.
- Lucigen Corporation
- Jena Biosciences
- Bio-Rad Laboratories, Inc.
Recent Developments
- In November 2023: A prominent company in the field of molecular biology, ‘BioEcho Lifesciences’, introduced the EcoLUTION FFPE RNA kit. This kit provides researchers with a streamlined technique and high quality RNA for their investigations. The isolated RNA is prepared for utilization in RT-qPCR, resulting dependable outcomes.
- In August 2023: HiMedia received approval for the commercial manufacture of their influenza PCR detection kit, along with DNA/RNA extraction kits and PCR reagents.
